Latest reference on how much does a box of Daprodustat cost?

Daprodustat (Daprodustat), as a new generation of HIF-PHI drugs, is mainly used to treat anemia related to chronic kidney disease, especially in patients who have received dialysis treatment. The significance of its application is to provide a new oral solution for the management of anemia and avoid the limitations of patients' long-term dependence on injectable preparations. Currently, the drug has been approved and marketed in some overseas countries, becoming an important treatment option for patients with chronic kidney disease.

In the Chinese market, daprostat has not yet been approved for marketing, and therefore has not been included in the scope of medical insurance reimbursement. For domestic patients, the drug cannot be obtained directly through regular hospitals, and its price lacks official reference information in the domestic market. However, in overseas markets, there is already certain public data on the price of dapinostat. According to information from international pharmaceutical sales channels, the common specifications of the drug include 1 mg 30 tablets, 2 mg 30 tablets, etc. Each box is sold for about US$100 to US$500, and the price fluctuates greatly when equivalent to RMB, which is mainly affected by the exchange rate and the drug pricing policies of various countries.

Generic drugs of dapoprimostat have appeared in overseas markets. The drug ingredients are consistent with the original drug, and the production process also meets quality standards. For example, the price of 1mg*100 tablets produced by Lucius Pharmaceuticals in Laos may be more than 400 yuan per box, which is much lower than the price of the original drug. The launch of generic drugs undoubtedly provides more affordable options for patients on long-term treatment, and also promotes the improvement of drug accessibility.

From the perspective of clinical application, daprostat not only improves the symptoms of anemia, but may also reduce the risk of patients caused by blood transfusion or high-dose erythropoietin therapy. In international guidelines, HIF-PHI drugs have gradually been included in the scope of consideration, which means that their market potential is huge in the future. As the introduction of new drugs in China accelerates, daprostat is expected to enter the Chinese market in the near future. Once medical insurance negotiations are successful, its price may drop significantly, thus benefiting more patients. At present, if patients want to use the drug, they still mainly rely on cross-border drug purchase channels. Therefore, they need to pay attention to the formality and safety of the source of the drug when choosing.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat